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Abstract
Background: As the epidemic of MDR-TB and XDR-TB becomes increasingly severe, it is important to determine
the clinical characteristics and molecular epidemiology of MDR-TB and XDR-TB. Recently, many studies have shown
that clinical features and molecular characteristics of drug-resistant strains vary in different geographical areas,
however, further information is needed to assess the dynamic evolution of drug-resistant TB. Comparative studies
between different time periods are necessary to elucidate the development of drug-resistant TB.
Results: A total of 255 and 537 strains were collected from Beijing Chest Hospital in 2006 and in 2012, respectively.
Drug-resistance rates and mutations associated with resistance to first-line anti-tuberculosis (TB) drugs were
compared. The overall rate of drug resistance among strains of TB in 2012 was 54.4 %, significantly higher than that
in 2006 (34.9 %, P < 0.001). Rates of resistance to each first-line drug (isoniazid, rifampicin, streptomycin and
ethambutol) and to second-line drug ofloxacin increased significantly from 2006 to 2012. The overall MDR rate also
increased significantly from 2006 (14.9 %) to 2012 (27.0 %). The rate of MDR increased significantly between these
two time periods in previously treated cases (P = 0.023) but not in new cases (P = 0.073), and the rate of XDR was
similar in new cases at the two time periods, but was marginally higher in 2012 in previously treated cases (P = 0.056).
Previous treatment was found to be a risk factor for drug-resistant TB, especially for MDR-TB. In addition, the proportion
of drug resistant isolates in which katG, the mabA-inhA promoter, oxyR-ahpC intergenic region, rpoB, rpsL, and embB
were mutated was similar in 2006 and 2012, however patterns of mutation in these loci were more diverse in 2012
compared to 2006.
Conclusions: Our data suggests that the prevalence of drug resistant TB remains high in Beijing, China, and that
increasing rates of resistance in M. tuberculosis to all anti-TB drugs should be considered when choosing an optimal
anti-TB regimen. Moreover, acquired multi-drug resistance may play a primary role in the MDR-TB epidemic in Beijing,
China. Consequently, this highlights the importance of an earlier start to effective and supervised treatment in order to
reduce the burden of retreatment.
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Background
Although the incidence and mortality of tuberculosis
(TB) have declined over the past decade, there were an
estimated 9.0 million incident cases of TB and 1.5
million deaths in 2013 according to the World Health
Organization [1]. Two major factors, including the lethal
association of HIV with active TB disease, and the
worldwide dissemination of multidrug-resistant (MDR)
and extremely drug-resistant (XDR) strains of Mycobac-
terium tuberculosis, contribute to the severe TB epi-
demic [1]. Globally, an estimated 3.5 % of new cases and
20.5 % of previously treated cases have MDR-TB. In
2013 there were an estimated 480, 000 new cases of
MDR-TB, and about 210, 000 associated deaths [1].
China is one of the 27 MDR-TB high-burden countries.
According to the 2007 national survey of drug-resistant
TB in China, 5.7 % of new cases and 25.6 % of previously
treated cases were diagnosed with MDR-TB. Based on
these survey results, it is estimated that there are 120,
000 new cases of MDR-TB in China per year [2]. In
addition, XDR-TB cases were reported by over 100
countries in 2013, and up to 9.0 % of MDR-TB cases
had XDR-TB in 2013 [1]. It is therefore urgent to con-
trol the epidemic of MDR-TB and XDR-TB.
In order to understand how drug-resistant TB de-
velops and to find better ways to control MDR-TB and
XDR-TB, it is essential to determine the clinical charac-
teristics and molecular epidemiology of MDR-TB and
XDR-TB. Recently, many studies have shown that
clinical features and molecular characteristics of drug-
resistant strains vary in different geographical areas
[3, 4], such as, for example in different provinces in
China [5–9]. These studies, however, have focused on
the clinical and molecular characteristics of drug-
resistant M. tuberculosis strains from a single time
period, and are thus unable to assess the dynamic
evolution of drug-resistant TB. Comparative studies
between different time periods are thus necessary to
elucidate the development of drug-resistant TB.
To better understand changes in the clinical and mo-
lecular characteristics of M. tuberculosis isolates in
Beijing, China, we analyzed all strains collected from TB
inpatients admitted to Beijing Chest Hospital (tertiary
TB referral hospital) over two time periods separated by
six years (2006 and 2012). Clinical information, drug-
resistant phenotypes (including MDR and XDR pheno-
types) and first-line drug resistance-associated mutations
were compared between these two time periods.
Results
Demographic and clinical characteristics of enrolled
subjects
Our purpose in this study was to evaluate changes in the
clinical characteristics and molecular epidemiology of
drug-resistant TB and thus assess its dynamic evolution.
We thus performed a comparative study of M. tubercu-
losis isolates collected at the Beijing Chest Hospital over
two time periods separated by 6 years. The MTB strain
bank at Beijing Chest Hospital was first established in
2005, and complete datasets were available for each year
from 2006 to 2012 when we initiated this project. We
reasoned that a 6-year window would reveal possible
changes in the rate of occurrence of drug-resistant TB,
so chose to analyze all isolates collected from inpatients
in the Beijing Chest Hospital from 2006 to 2012. A total
of 792 isolates were selected, including 255 and 537 iso-
lates from 2006 to 2012, respectively. The mean age of
patients in 2006 and 2012 was 48.8 ± 19.5 years and
51.4 ± 19.6 years, and the male to female ratio was 2.7
and 2.9, respectively.
As shown in Table 1, there were no significant differences
in the clinical characteristics (including gender, age and
treatment history) of each subgroup (any drug-resistant
TB, MDR-TB and pan-susceptible TB cases) between cases
in 2006 and 2012 (P > 0.05). Of note, however, the propor-
tion of previously treated cases in 2012 (40.8 %) was signifi-
cantly higher than that in 2006 (31.0 %, P = 0.008).
Drug-resistance patterns differ in 2006 and 2012
The overall rate of resistance in the MTB strains exam-
ined to any drug was 54.4 % in 2012, significantly higher
than that in 2006 (34.9 %, P < 0.001), indicating the se-
vere and worsening situation of drug-resistance in TB in
China. Furthermore, the rate of resistance to any drug in
2012 was higher than that in 2006 in both new and pre-
viously treated cases (P < 0.05).
The proportion of drug-resistant M. tuberculosis isolates
in 2006 was compared with that in 2012 (Table 2). The
overall resistance level to each drug was significantly
higher in 2012 (P < 0.05). Rates of resistance to rifampicin
(RIF), streptomycin (STR), ethambutol (EMB) and ofloxa-
cin (OFX) were significantly higher in new cases in 2012
(P < 0.05), while the proportion of isolates resistant to iso-
niazid (INH) were marginally higher (P = 0.054), and re-
sistance to capreomycin (CAP) and amikacin (AMK) was
not significantly changed (P > 0.05). The proportions of
isolates resistant to INH, RIF, OFX and CAP in previously
treated cases were significantly higher in 2012 (P < 0.05),
but the proportions of isolates resistant to STR, EMB and
AMK were not significantly changed (P > 0.05).
The overall rate of MDR-TB was 27.0 % in 2012, sig-
nificantly higher than that in 2006 (14.9 %, P < 0.05).
The proportion of MDR-TB in previously treated cases was
significantly higher in 2012 compared to 2006 (P = 0.023),
but there was no significant increase in new cases
(P = 0.073). The overall pre-XDR rate was 13.6 % in
2012, again, significantly higher than that in 2006
(6.7 %, P = 0.004). However, the pre-XDR rate in 2012 did
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not increase significantly in either new cases (P = 0.165) or
previously treated cases (P = 0.090) compared with 2006.
The rate of XDR-TB also increased significantly from
2006 (2.4 %) to 2012 (6.9 %). While the rate of XDR
was similar in new cases during the two time periods,
it was marginally higher in 2012 in previously treated
cases (P = 0.056).
Factors associated with drug-resistant TB and MDR-TB
The risk factors associated with resistance to any
drug and MDR-TB were analyzed based on pooled
demographic data for all patients (Table 3). By univariate
analysis, age and treatment history were significantly asso-
ciated with resistance to any drug and MDR-TB (P < 0.05).
Multivariate analysis confirmed that age and treatment
history were independently associated with resistance to
any drug and MDR-TB (P < 0.05).
Patients older than 64 years had a significantly lower
risk of developing drug resistance relative to patients in
the younger age group (<25 years), with an adjusted OR
of 0.52 (95 % CI: 0.31–0.86, P = 0.002). This risk de-
creased significantly in MDR-TB cases, with an adjusted
Table 1 General demographic characteristics of patients enrolled in 2006 and 2012



















Male 186 (72.9) 400 (74.5) 0.643 66 (74.2) 223 (76.4) 0.669 29 (76.3) 102 (70.3) 0.468 120 (72.3) 177 (72.2) 0.990
Female 69 (27.1) 137 (25.5) 23 (25.8) 69 (23.6) 9 (23.7) 43 (29.7) 46 (27.7) 68 (27.8)
Age group (years)
~25 41 (16.1) 76 (14.2) 0.682 14 (15.7) 46 (15.8) 0.728 6 (15.8) 32 (22.1) 0.428 27 (16.4) 30 (11.9) 0.271
~44 60 (23.5) 125 (23.3) 23 (25.8) 82 (28.1) 11 (28.9) 53 (36.6) 37 (20.9) 43 (17.5)
~64 92 (36.1) 185 (34.5) 38 (42.7) 107 (36.6) 18 (47.4) 48 (33.1) 54 (32.2) 78 (32.5)
>64 62 (24.3) 151 (28.1) 14 (15.7) 57 (19.5) 3 (7.9) 12 (8.3) 48 (30.5) 94 (38.1)
Treatment history
New cases 176 (69.0) 318 (59.2) 0.008 37 (41.6) 115 (39.4) 0.712 5 (13.2) 21 (14.5) 0.835 139 (83.7) 203 (82.9) 0.815
Previously
treated cases
79 (31.0) 219 (40.8) 52 (58.4) 177 (60.6) 33 (86.8) 124 (85.5) 27 (16.3) 42 (17.1)
Table 2 Comparison of drug susceptibility patterns between clinical M. tuberculosis isolates in 2006 and in 2012
Susceptibility or resistance
category
Total cases New cases Previously treated cases
2006 (n = 255)
n (%)
2012 (n = 537)
n (%)
P value 2006 (n = 176)
n (%)
2012 (n = 318)
n (%)
P value 2006 (n = 79)
n (%)
2012 (n = 219)
n (%)
P value
Any drug-resistance 89 (34.9) 292 (54.4) <0.001 37 (21.0) 115 (36.2) 0.001 52 (65.8) 177 (80.8) 0.007
All first-line drug resistance 78 (30.6) 269 (50.1) <0.001 30 (17.0) 98 (30.8) 0.001 48 (60.8) 171 (78.1) 0.003
INH 60 (23.5) 209 (38.9) <0.001 20 (11.4) 57 (17.9) 0.054 40 (50.6) 152 (69.4) 0.003
RIF 43 (16.9) 164 (30.5) <0.001 5 (2.8) 30 (9.4) 0.006 38 (48.1) 134 (61.2) 0.044
STR 59 (23.1) 189 (35.2) 0.001 21 (11.9) 63 (19.8) 0.026 38 (48.1) 126 (57.5) 0.149
EMB 24 (9.4) 88 (16.4) 0.008 8 (4.5) 31 (9.7) 0.040 16 (20.3) 57 (26.0) 0.306
All MDR 38 (14.9) 145 (27.0) <0.001 5 (2.8) 21 (6.6) 0.073 33 (41.8) 124 (56.6) 0.023
INH + RIF 4 (2.0) 25 (4.5) 0.079 1 (0.6) 4 (1.3) 0.463 3 (3.8) 21 (9.6) 0.105
INH + RIF + STR/EMB 34 (13.3) 120 (22.3) 0.003 4 (2.3) 17 (5.3) 0.105 30 (38.0) 103 (47.0) 0.165
All second-line drug
resistance
40 (15.7) 172 (32.0) <0.001 14 (8.0) 45 (14.2) 0.042 26 (32.9) 127 (58.0) <0.001
OFX 37 (14.5) 164 (30.5) <0.001 13 (7.4) 42 (13.2) 0.049 24 (30.4) 122 (55.7) <0.001
CAP 1 (0.4) 29 (5.4) 0.001 1 (0.6) 2 (0.6) 0.934 0 27 (12.3) 0.001
AMK 9 (3.5) 42 (7.8) 0.021 1 (0.6) 7 (2.2) 0.168 8 (10.1) 35 (16.0) 0.204
All pre-XDR 17 (6.7) 73 (13.6) 0.004 2 (1.1) 10 (3.1) 0.165 15 (19.0) 63 (28.8) 0.090
All XDR 6 (2.4) 36 (6.9) 0.008 1 (0.6) 4 (1.3) 0.463 5 (6.3) 32 (14.6) 0.056
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Table 3 Factors associated with drug-resistant tuberculosis in all patients
Factors Resistance to any




TB (n = 411)
MDR-TB vs Pan-susceptible TB Resistance to any drug vs Pan-susceptible TB
Odds ratio
(95 % CI)
P value Adjusted odds
ratio (95 % CI)
P value Odds ratio
(95 % CI)
P value Adjusted odds
ratio (95 % CI)
P value
Gender
Male 289 131 297 Reference Reference
Female 92 52 114 1.03 (0.70–1.52) 0.865 0.83 (0.60–1.14) 0.250
Age group (years)
~25 60 38 57 Reference Reference Reference Reference
~44 105 64 80 1.20 (0.71–2.03) 0.892 1.05 (0.51–2.19) 0.718 1.25 (0.78–1.99) 0.734 1.09 (0.65–1.83) 0.625
~64 145 66 132 0.75 (0.45–1.24) 0.155 0.60 (0.30–1.21) 0.033 1.04 (0.68–1.61) 0.969 0.99 (0.61–1.60) 0.610
>64 71 15 142 0.16 (0.08–0.31) <0.001 0.12 (0.05–0.27) <0.001 0.48 (0.30–0.75) 0.011 0.52 (0.31–0.86) 0.002
Treatment history
New cases 152 26 342 Reference Reference Reference Reference












OR of 0.12 (95 % CI: 0.05–0.27, P < 0.001). Previously
treated cases were associated with a higher risk of devel-
oping drug resistance, with an adjusted OR of 7.11 (95 %
CI: 5.09–9.92, P < 0.001), and the risk increased signifi-
cantly in MDR-TB cases, with an adjusted OR of 32.64
(95 % CI: 19.40–54.92, P < 0.001).
Drug resistance associated mutations in 2006 and 2012
Using a combination of mutations in katG, the mabA-
inhA promoter and the oxyR-ahpC intergenic region,
DNA sequencing was able to identify 86.7 % (52/60) and
85.6 % (179/209) of INH-resistant isolates collected in
2006 and 2012, respectively. Similarly, 88.4 % (38/43)
and 92.1 % (151/164) of RIF-resistant isolates were de-
tected based on mutations in the RRDR region of rpoB,
79.7 % (47/59) and 76.2 % (144/189) of STR-resistant
isolates were detected based on mutations in rpsL, and
54.2 % (13/24) and 62.5 % (55/88) of EMB-resistant
isolates were detected based on mutations in embB. In
addition, 8.2 % (19/231) and 11.4 % (51/449) of EMB-
susceptible isolates in the 2006 and 2012 groups were
also found to harbor mutations in the embB gene. Other
target mutations were not found in INH, RIF and STR
susceptible isolates in the 2006 and 2012 collections.
The frequencies of common mutations in INH, RIF,
STR or EMB resistant isolates were similar in 2006 and
in 2012: katG315 (71.7 % vs 58.4 %, P = 0.062), mabA-
inhA −15 (15.0 % vs 19.6 %, P = 0.418); rpoB531 (55.8 %
vs 63.4 %, P = 0.361), rpoB526 (16.3 % vs 17.1 %, P = 0.902);
rpsL43 (64.4 % vs 64.0 %, P = 0.975); embB306 (33.3 % vs
35.2 %, P = 0.863). Data on common mutation patterns in
these drug-resistant isolates are shown in Table 4. In
addition, the embB306 mutation was detected in
4.5 % (11/231) and 6.5 % (29/449) of EMB-susceptible
isolates in the 2006 and 2012 collections, respectively.
Moreover, patterns of mutation in the loci examined
were more diverse in 2012 compared to 2006.
Discussion
In this hospital-based study, the rate of resistance to any
drug and the MDR rate of M. tuberculosis isolates was
found to increase significantly from 2006 to 2012,
reflecting the serious drug-resistant TB epidemic in
China. Overall, the percentage of previously treated
cases in 2012 was higher than that in 2006, suggesting
that treatment of previously treated cases is still a big
challenge in controlling the TB epidemic in China. Fur-
thermore, the proportion of previously treated cases
among the MDR-TB cases increased to 40.8 % in 2012
compared to that in 2006 (31.0 %). This implies that ac-
quired multi-drug resistance may play an increasing role
in the MDR-TB epidemic in China.
Among the new TB cases in this study, rates of resist-
ance to each first-line drug in the 2006 isolate collection
were consistent with those found in the National survey
of drug-resistant TB conducted in 2007 [2]. However,
rates of resistance to each first-line drug were signifi-
cantly increased in 2012. The rate of resistance to the
second-line drug OFX also increased from 7.4 % in 2006
to 13.2 % in 2012 among new TB cases. The increasing
rate of OFX resistance rate should thus be considered
when choosing an optimal anti-TB regimen. As the new
cases in this study had not received therapy or were in
treatment for less than 1 month, the rate of drug resist-
ance among new cases should reflect the transmission of
drug-resistant TB.
Among previously treated cases examined in our
study, rates of resistance of M. tuberculosis isolates to
INH, RIF, OFX and CAP were also higher in the 2012
collection compared with the 2006 collection. Overall
rates of drug-resistance to each first-line drug in 2006
were much higher than that in the National survey [2].
This difference might be attributed to differences in
sampling methods and the subjects targeted. For the
national survey, isolates were selected from across 10
provinces of China using a cluster-randomized sampling
method [2]. In contrast, in this study, patients were re-
cruited from one tertiary TB referral hospital, i.e., most
subjects were hospitalized TB patients with relatively
serious symptoms. Overall, the increasing rate of drug-
resistance in previously treated cases underlines the im-
portance of standard treatment and the necessity of opti-
mizing the treatment regimen according to the results of
drug susceptibility testing.
The MDR and XDR rates in the 2006 isolates were simi-
lar to those found in the National survey [2] among new
cases, but were much higher for previously treated cases.
This may also be due to differences in the patients tar-
geted as discussed above. Moreover, the rates of MDR and
XDR MTB isolates had increased in 2012 compared to
2006 both among new cases and previously treated cases,
although the difference was not significant for new cases.
This data suggests that acquired MDR might outweigh
primary resistance in the MDR epidemic in China. This
finding is different from that of Gao et al. [10] who found
that it is recent transmission of M. tuberculosis including
transmission of MDR strains, that contributes most highly
to the TB epidemic in China. This difference in findings
may be due to variation in regions sampled: Gao et al. col-
lected strains from five counties within five different prov-
inces [10], while the study population examined here
came from one hospital in Beijing. Previous studies have
shown that drug-resistance rates vary in different prov-
inces [11]. Pre-XDR rates increased significantly from
2006 to 2012. Since pre-XDR is an important step in the
development of drug resistance from MDR to XDR, this
finding presents an additional alarming indication of the
worsening situation of XDR-TB in China.
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Relative frequency % (No. of mutant
isolates/No. of drug-resistant isolates)
Mutated
patterns
Relative frequency % (No. of mutant
isolates/No. of drug-resistant isolates)
Mutated
patterns
Relative frequency % (No. of mutant
isolates/No. of drug-resistant isolates)
INH katG Codon 315 AGC→ACC 68.3 (41/60) AGC→ACC 56.5 (118/209) AGC→ACC 59.1 (159/269)
AGC→ACA 1.7 (1/60) AGC→ACA 0.5 (1/209) AGC→ACA 0.7 (2/269)
AGC→AAC 1.7 (1/60) AGC→AAC 1.0 (2/209) AGC→AAC 1.1 (3/269)
AGC→CGC 0.5 (1/209) AGC→CGC 0.3 (1/269)
Other mutations – 0 – 7.7 (16/209) – 6.0 (16/269)
mabA-inhA promoter −15 −15 C→T 15.0 (9/60) −15 C→T 19.6 (41/209) −15 C→T 18.6 (50/269)
Other mutations – 6.7 (4/60) – 3.3 (7/209) – 4.1 (11/269)
oxyR-ahpC intergenic
region
−10 −10 C→T 0 −10 C→T 2.4 (5/209) −10 C→T 1.9 (5/269)
−30 −30 C→T 1.7 (1/60) −30 C→T 0 −30 C→T 0.4 (1/269)
−39 −39 C→T 0 −39 C→T 2.4 (5/209) −39 C→T 1.9 (5/269)
Other mutations – 1.7 (1/60) – 3.8 (8/209) – 3.3 (9/269)
RIF rpoB RRDR Codon 531 TCG→TTG 53.5 (23/43) TCG→TTG 60.4 (99/164) TCG→TTG 58.9 (122/207)
TCG→TGG 2.3 (1/43) TCG→TGG 1.2 (2/164) TCG→TGG 1.4 (3/207)
TCG→TTC 1.2 (2/164) TCG→TTC 1.0 (2/207)
TCG→CAG 0.6 (1/164) TCG→CAG 0.5 (1/207)
Codon 526 CAC→TAC 9.3 (4/43) CAC→TAC 7.3 (12/164) CAC→TAC 7.7 (16/207)
CAC→GAC 4.7 (2/43) CAC→GAC 2.4 (4/164) CAC→GAC 2.9 (6/207)
CAC→AAC 2.3 (1/43) CAC→AAC 1.2 (2/164) CAC→AAC 1.4 (3/207)
CAC→CTC 4.3 (7/164) CAC→CTC 3.4 (7/207)
CAC→ACC 0.6 (1/164) CAC→ACC 0.5 (1/207)
CAC→GTC 0.6 (1/164) CAC→GTC 0.5 (1/207)
CAC→TGC 0.6 (1/164) CAC→TGC 0.5 (1/207)
Other mutations – 16.3 (7/43) – 11.6 (19/164) – 12.6 (26/207)
STR rpsL Codon 43 AAG→AGG 59.3 (35/59) AAG→AGG 63.5 (120/189) AAG→AGG 62.5 (155/248)
AAG→AAC 5.1 (3/59) AAG→ACG 0.5 (1/189) AAG→AAC 1.2 (3/248)
AAG→ACG 0.4 (1/248)
Other mutations – 15.3 (9/59) – 12.2 (23/189) – 12.9 (32/248)
EMB embB Codon 306 ATG→GTG 25.0 (6/24) ATG→GTG 19.3 (17/88) ATG→GTG 29.5 (23/112)
ATG→ATA 8.3 (2/24) ATG→ATA 11.4 (10/88) ATG→ATA 10.7 (12/112)












Table 4 Most frequently identified mutations within first-line drug-resistance associated loci among drug-resistant M. tuberculosis isolates (Continued)
ATG→ATC 1.1 (1/88) ATG→ATC 0.9 (1/112)
ATG→CTG 1.1 (1/88) ATG→CTG 0.9 (1/112)












Previous treatment is a well-known risk factor for
drug-resistant TB and MDR-TB, and the prevalence of
MDR-TB can be up to 10 times higher after unsuccessful
treatment [12]. In this sense, results obtained here are
consistent with previous observations: the risk of suffer-
ing MDR-TB among previously treated cases was 32.64
times higher than that in new cases. The implementation
of DOTS is thus still very important for effectively con-
trolling drug-resistant TB and MDR-TB, especially with
respect to supervising patients to complete the treat-
ment. We also found that people older than 64 years of
age had a lower risk of drug-resistant TB and MDR-TB.
This is consistent with the conclusion of a systematic
review of European studies which concluded that
MDR-TB cases are more likely to occur in patients
younger than 65 years of age [13]. The higher risk of
getting MDR-TB in people under 65 years may be at-
tributed to the use of RIF for anti-TB treatment from
around 1965. TB cases in older patients are usually
considered as relapse cases, and the infecting strains
may be more ancient, and carry a lower risk of be-
coming resistant to RIF.
Between 2006 and 2012, there was more or less no dif-
ference in the molecular detection rate for first line
drug-resistance in our study. It should be noted that
mutations in embB were also found in EMB-susceptible
isolates [14]. Here, embB306 mutations were found in
4.5 % and 6.5 % of EMB-susceptible isolates in 2006 and
2012, respectively. This percentage is lower than previ-
ously reported in Russia (31.2 %) [14] and Singapore
(20.0 %) [15], and may be due to different percentages of
multi-drug resistance among EMB-susceptible isolates.
Hazbon et al. collected 807M. tuberculosis isolates from
Colombia, Mexico, New York and Texas, and found that
the association between embB306 mutations and resist-
ance to increasing numbers of anti-TB drugs was signifi-
cant in each region, suggesting the role of embB306
mutations in broad drug resistance [16]. The frequency
of the embB306 mutation in one setting may thus be in-
fluenced by the percentage of multi-drug resistant iso-
lates. Accordingly, the embB306 mutation does not
appear to be a reliable marker for predicting EMB resist-
ance in Beijing, China.
Mutation rates at common loci in specific genes asso-
ciated with drug-resistance were similar in 2006 and
2012. It has previously been shown that antibiotic resist-
ance associated mutations can impair bacterial fitness
[17, 18]. However, acquisition of compensatory muta-
tions in drug resistant strains can restore their ability to
survive. It is possible that the reason why the mutation
rate at common loci in the drug-resistant isolates in our
study was unchanged may be that mutations in these
common loci are associated with other compensatory
mutations that lead to lower fitness costs.
Our study, however, has some limitations. The isolates
examined were collected from only one TB referral hos-
pital in Beijing. Patients admitted to this hospital tend to
be severe cases or to have received therapy in other hos-
pitals but with poor effect. Thus the incidence of drug-
resistant TB may be overestimated, and may not reflect
the average level of the whole country. Well-designed
studies with a wide coverage of different regions in
China should thus be conducted in the future.
Conclusions
Results from this study indicate that the prevalence of
drug resistant TB remains high in Beijing, China, and
suggest that increasing rates of resistance in M. tuber-
culosis to all anti-TB drugs should be considered
when choosing optimal anti-TB regimens for treat-
ment. The rate of MDR and XDR in M. tuberculosis
isolates was higher in 2012 compared to 2006, espe-
cially in isolates from previously-treated cases, sug-
gesting that acquired multi-drug resistance may
increasingly be playing a primary role in the MDR-TB
epidemic in China. These findings highlight the im-
portance of an earlier start on effective and super-
vised treatment in order to reduce the burden of
retreatment.
Methods
M. tuberculosis isolates and drug susceptibility
testing (DST)
A total of 255 and 537M. tuberculosis isolates collected
in 2006 and 2012, respectively, were obtained from
Beijing Bio-Bank of clinical resources on Tuberculosis at
Beijing Chest Hospital. All isolates were recovered from
inpatients diagnosed with pulmonary TB. If several iso-
lates had been recovered from the same patient at differ-
ent time points, only the earliest isolate was included in
this analysis. Clinical investigations were conducted in
accordance with the principles expressed in the Declar-
ation of Helsinki, and this study was approved by the
Ethics Committee of Beijing Chest Hospital. Written in-
formed consent was not obtained from patients as the
data were analyzed anonymously.
DST was performed using the proportion method on
Löwenstein-Jensen medium, according to WHO guide-
lines, with the following concentrations of anti-TB
drugs: INH - 0.2 μg/ml, RIF - 50 μg/ml, STR - 10 μg/ml,
EMB - 5.0 μg/ml, OFX - 2.0 μg/ml, levofloxacin (LFX) -
2.0 μg/ml, CAP - 40 μg/ml, AMK - 30 μg/ml. Strains
were deemed to be resistant to a specific drug when the
growth rate was ≥1 % that of the control. Both OFX and
LFX susceptibility testing were performed, but as results
showed that all LFX-resistant isolates were also resistant
to OFX, LFX-resistance data were not included in the
analysis.
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Data collection and definitions
Demographic and clinical information on enrolled pa-
tients, including gender, age, address and TB treatment
history, were obtained from inpatients’ medical records.
New cases were TB patients who had never been treated
with anti-TB drugs or that had been treated for less than
1 month. Previously treated cases were TB patients who
had been treated with anti-TB drugs for 1 month or lon-
ger. MDR-TB was defined as resistance to at least INH
and RIF [19]. Although kanamycin resistance is included
in the WHO definition of pre-XDR and XDR, this drug
is rarely used to treat TB at the Beijing Chest Hospital.
In this study, XDR-TB was therefore defined as resist-
ance to INH and RIF plus OFX and at least one inject-
able second-line drug (CAP or AMK). Pre-XDR TB was
defined as resistance to INH and RIF plus either OFX or
a second-line injectable drug (CAP or AMK), but not
both.
Detection of drug resistance associated gene mutations
Loci associated with hot-spots of drug-resistance to first
line anti-TB drugs (INH, RIF, STR and EMB), including
katG, the mabA-inhA promoter, oxyR-ahpC intergenic
region, rpoB RRDR (RIF-resistance-determining region),
rpsL and embB were sequenced in this study. Genomic
DNA was extracted from freshly cultured M. tubercu-
losis using a conventional cetyltrimethylammonium
bromide (CTAB) method [20]. All the primers for
amplification of target nucleotide positions and DNA
sequencing are listed in Table 5. For each target gene,
the volume of PCR mixture was 25 μL, containing
12 μL of 2× Taq Master Mix, 1 μL of forward and re-
verse primers (10 μΜ), 10 μL of distilled H2O and
1 μL of genomic DNA. For katG, rpoB RRDR, embB,
and rpsL, the PCR program comprised an initial de-
naturation at 95 °C for 3 min, followed by 35 cycles
of 94 °C for 45 s, 62 °C for 45 s and 72 °C for 35 s,
and a final step of 72 °C for 4 min. For the mabA-
inhA promoter and oxyR-ahpC intergenic region, the
PCR program comprised an initial denaturation at
95 °C for 5 min, followed by 35 cycles of 94 °C for
1 min, 62 °C for 1 min and 72 °C for 1 min, and a final
step of 72 °C for 4 min. All PCR products were sent for se-
quencing using primers which were the same as those
used for PCR amplification. Sequencing data was aligned
with the corresponding sequences of the M. tuberculosis
H37Rv reference strain using BLASTn optimized for
megablast on the National Center for Biotechnology In-
formation website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis
Pearson chi-square tests or Fisher exact tests were
used to compare drug-resistance rates between iso-
lates collected in 2006 and in 2012. Univariate
analysis of categorical variables was performed with
the Pearson chi-square test or Fisher exact test as ap-
propriate. Univariate and multivariate logistic regres-
sion analyses were used to analyze drug-resistance-
associated risk factors. Variables with a P value less
than 0.05 in the univariate analysis were analysed fur-
ther by multivariable logistic regression analysis. A
two-sided P value of <0.05 was considered statistically
significant. Statistical analyses were performed using
SPSS statistics 19.0.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of
Beijing Chest Hospital. Written informed consent was
not obtained from patients as the data were analyzed
anonymously.
Availability of data and materials
All of the data are complete in this study, no supple-
mentary data are attached.
Table 5 Primers for PCR amplification and DNA sequencing
Gene Amplified Region (bp) Orientation Oligonucleotide sequence (5′–>3′) Tm (°C)
katG 580 to 1257 Forward GATGAGGTCTATTGGGGCAAG 59.8
Reverse GTCTCGGTGGATCAGCTTGTA 59.8
mabA-inhA promoter −436 to 182 (mabA) Forward ATGCGCTCTTCCCAGACTT 58.0
Reverse TCACATTCGACGCCAAACAG 60.0
OxyR’-ahpC intergenic region 285 (oxyR’) to 312 (ahpC) Forward CCCTCATGCAGTCACAACAA 60.0
Reverse TTTGAGGTCGTTGTGCTGTG 60.0
rpoB RRDR 916 to 1572 Forward GGTCGCTATAAGGTCAACAAGAAG 61.0
Reverse GTACACGATCTCGTCGCTAACC 62.1
embB 847 to 1581 Forward GTGATATTCGGCTTCCTGCTCT 60.2
Reverse GTAGTAGTAACGCAGGTTCTCGGTA 62.9
rpsL 254 to 877 Forward GAATCGAGTTTGAGGCAAGCTAT 58.8
Reverse CTCAAGCGCACCATAAACAAT 55.9
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